Skip to main content
. 2018 Oct 26;19(11):3334. doi: 10.3390/ijms19113334

Figure 1.

Figure 1

Kaempferitrin (KM) increases the cell viability of advanced glycation end (AGE)-treated glomerular mesangial cells (GMCs). GMCs were pre-treated with different concentrations of KM and then stimulated with AGEs (160 μg/mL) for 24 h. The results are presented as mean ± standard errors of the means (SEM). ** p < 0.01, vs. AGEs group; ## p < 0.01, vs. control group.